Real-world experience with 11C-methionine PET in the management of acromegaly.
Linus HaberboschJames MacFarlaneOlympia KoulouriDaniel GillettAndrew S PowlsonSue OddyDavid J HalsallKevin A HuynhJonathan JonesHeok K CheowJoachim SprangerKnut MaiChristian StrasburgerRichard J MannionMark GurnellPublished in: European journal of endocrinology (2024)
In patients with persistent/recurrent acromegaly or occult tumours, Met-PET can facilitate further targeted intervention (surgery/radiosurgery). This led to complete remission in most cases (24/33) or significant improvement with comparatively low risk of complications. Met-PET should therefore be considered in all patients who are potential candidates for further surgical intervention, but present no clear target on MRI.
Keyphrases
- computed tomography
- pet ct
- positron emission tomography
- randomized controlled trial
- end stage renal disease
- pet imaging
- ejection fraction
- chronic kidney disease
- newly diagnosed
- minimally invasive
- tyrosine kinase
- magnetic resonance imaging
- prognostic factors
- risk factors
- contrast enhanced
- small cell lung cancer
- rheumatoid arthritis
- coronary artery bypass
- magnetic resonance
- acute coronary syndrome
- cancer therapy
- brain metastases
- risk assessment
- ulcerative colitis
- human health
- percutaneous coronary intervention